{
    "nct_id": "NCT02940483",
    "official_title": "Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle or Resection Cavity in Children With Recurrent Posterior Fossa Ependymoma: A Pilot Study",
    "inclusion_criteria": "* Diagnosis: Patients with histologically verified ependymoma, with recurrence or progression involving anywhere in the brain and/or spine. To be eligible, patients' disease must have originated in the posterior fossa of the brain.\n* Patient must have either measurable or evaluable tumor as assessed by MRI of the brain and total spine.\n* An implanted catheter in the fourth ventricle or posterior fossa tumor cavity attached to a ventricular access device or agreement to have one placed.\n* A minimum of 7 days between last dose of systemic chemotherapy and/or radiation therapy and first infusion of 5-Azacytidine into fourth ventricle.\n* Life expectancy of at least 12 weeks in the opinion of the PI\n* Lansky score of 50 or greater if ≤16 years of age or Karnofsky score of 50 or greater if > 16 years of age.\n* Existing neurological deficits must have been stable for a minimum of 1 week prior to study enrollment.\n* Patients must have recovered from the acute toxic effects of all prior anticancer chemotherapy\n* Adequate bone marrow function defined by peripheral absolute neutrophil count (ANC) ≥ 500/µL, platelet count ≥ 50,000/ µL (transfusion independent), and hemoglobin ≥9.0 gm/dL (may receive RBC transfusions)\n* Patient or patient's legal representative, parent(s), or guardian able to provide written informed consent.\nHealthy volunteers allowed\nMust have minimum age of 1 Year\nMust have maximum age of 21 Years",
    "exclusion_criteria": "* Enrolled in another treatment protocol\n* Has received another investigational or chemotherapy agent or radiation therapy within 7 days prior to 5-Azacytidine infusion into the fourth ventricle.\n* Evidence of untreated infection\n* Pregnant of lactating women",
    "miscellaneous_criteria": ""
}